Lilly Registers Two Phase 3 Trials of EloraTZP, Its Eloralintide-Tirzepatide Combination

GLP-1 Newspaper: Daily Ozempic, Zepbound & Weight-Loss Drug News · Oct 27, 2026 · 5m · transcript

Eli Lilly has registered two phase 3 trials of EloraTZP, an investigational once-weekly combination of the amylin agonist eloralintide and tirzepatide (the active ingredient in Zepbound and Mounjaro), on ClinicalTrials.gov. We walk through how the trials are set up: AMPLIFY-1 plans to enroll about 2,115 adults with obesity and without diabetes and compares several EloraTZP doses with tirzepatide alone, eloralintide alone and placebo; AMPLIFY-2 plans to enroll about 1,000 adults with obesity or overweight and type 2 diabetes and compares EloraTZP with tirzepatide alone. Both trials measure…